Advertisement

NLA Scientific Statement on the Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk

Last Updated: Thursday, 17-Oct-2019 16:30:00 EDT

NLA Scientific Statement on the Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk

Carl E. Orringer, MD, FNLA; Terry A. Jacobson, MD, FNLA; Kevin C. Maki, PhD, FNLA
 

Highlights:

  • Hypertriglyceridemia is associated with increased ASCVD risk
  • Long chain omega-3 fatty acids lower circulating TG
  • Benefits of low dose omega-3 have been controversial
  • In REDUCE-IT icosapent ethyl demonstrated 25% net ASCVD risk reduction
  • NLA: Use icosapent ethyl in selected high TG ASCVD &/or diabetic patients on statin

 

Read Full Statement 

Resources

 

Podcast 

Podcast activity is not offered for CME/CE credit.
 
Access the Manuscript in the Journal of Clinical Lipidology Presentation Slides Infographic

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service